Venlafaxine XR in the treatment of anxiety

Hackett, D.

doi:10.1111/j.0065-1591.2000.acp29-05.x

Cited by 16 publications

(7 citation statements)

References 9 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, at the beginning of treatment, serotonergic agents may have a delayed onset of action and may even activate anxiety symptoms at first, with less than half of all patients experiencing complete remission of symptoms and at the cost of long-term side effects such as sexual dysfunction. 7,8 On the other hand, GABAergic benzodiazepines may have a rapid onset of action and boost early efficacy of serotonergic agents (if sedation can be avoided), and then be discontinued after shortterm administration, thus serving as a bridge to long-term serotonergic treatments. 9 Benzodiazepines can also serve as emergency relief for breakthrough anxiety over the long term, and in cases where serotonergic agents are unable to relieve all symptoms, can "top up" such treatments to lead to remission of anxiety.…”

Section: Combining Independent Mechanisms To Enhance Therapeutic Resultsmentioning

confidence: 99%

Don't Ask, Don't Tell, but Benzodiazepines Are Still the Leading Treatments for Anxiety Disorder

Stahl¹

2002

J. Clin. Psychiatry

View full text Add to dashboard Cite

Section: Combining Independent Mechanisms To Enhance Therapeutic Resultsmentioning

confidence: 99%

Don't Ask, Don't Tell, but Benzodiazepines Are Still the Leading Treatments for Anxiety Disorder

Stahl¹

2002

J. Clin. Psychiatry

View full text Add to dashboard Cite

“…The XR formulation of venlafaxine was developed to allow for prolonged duration of absorption and once-daily dosing, with the potential of an improved side-effect profile. 40 The efficacy of venlafaxine XR has been investigated in five outpatient placebo-controlled studies, which showed a consistent pattern of improvement in the treatment of GAD. 41 Four of these studies demonstrated a statistically superior improvement compared with placebo.…”

Section: Serotonin and Noradrenaline Reuptake Inhibitorsmentioning

confidence: 99%

WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder

Allgulander¹,

Bandelow²,

Hollander³

et al. 2003

CNS Spectr.

View full text Add to dashboard Cite

What are the current recommendations for the long-term treatment of generalized anxiety disorder (GAD)? GAD is a common disorder with a lifetime prevalence of 4% to 7% in the general population. GAD is characterized by excessive, uncontrollable worry or anxiety about a number of events or activities that the individual experiences on more days than not over a 6-month period. Onset of GAD symptoms usually occurs during an individual's early twenties; however, high rates of GAD have also been seen in children and adolescents. The clinical course of GAD is often chronic, with 40% of patients reporting illness lasting >5 years. GAD is associated with pronounced functional impairment, resulting in decreased vocational function and reduced quality of life. Patients with GAD tend to be high users of outpatient medical care, which contributes significantly to healtcare costs. Currently, benzodiazepines and buspirone are prescribed frequently to treat GAD. Although both show efficacy in acute treatment trials, few long-term studies have been perform Benzodiazepines are not recommended for long-term treatment of GAD, due to associated development of tolerance, psychomotor impairment, cognitive and memory changes, physical dependence, and a withdrawal reaction on discontinuation. The antidepressant venlafaxine extended-release (XR) has received approval for the treatment of GAD in the United States and many other countries. Venlafaxine XR has demonstrated efficacy over placebo in two randomized treatment trials of 6 months' duration as well as in other acute trials. Paroxetine is the first of the selective serotonin reuptake inhibitors (SSRIs) to receive US approval for the treatment of GAD. Paroxetine demonstrated superiority to placebo in short-term trials, and investigations into the use of other SSRIs are ongoing. This suggests that other SSRIs, and serotonin and noradrenaline reuptake inhibitors, are likely to be effective in the treatment of GAD. Of the psychological therapies, cognitive-behavioral therapy (CBT) shows the greatest benefit in treating GAD patients. Treatment gains after a 12-week course of CBT may be maintained for up to 1 year. Currently, no guidelines exist for the long-term treatment of GAD.

show abstract

“…Da die Patienten der TB auch hier die Therapie nach Beendigung der KKG mit einer insgesamt schwächer ausgeprägten Symptomatik begannen, ist der Prozentsatz an klinisch gesunden Patienten höher (n = 22, 84,6%) als in der TA (n = 16, 51,6%) (Tab. [Hackett et al, 2000;Gelenberg et al, 2000;Davidson et al, 1999;Rickels et al, 2000]. Unter Paroxetin lag der Rückgang bei 12 Punkten [Rocca et al, 1997;Pollack et al, 2001].…”

Section: Validierung Des Therapieeffekts: Vergleich Von Ta Und Tbunclassified

Wirksamkeit der kognitiven Verhaltenstherapie bei generalisierten Angsterkrankungen – Ergebnisseder Berliner KVT-GAD-Studie

Bär¹,

Zubrägel²,

Ahrens³

2002

Verhaltenstherapie

View full text Add to dashboard Cite

Effectiveness of the Cognitive Behavior Therapy in the Treatment of Generalized Anxiety Disorders – Results of the Berlin GAD-KVT-Study Background: In recent years generalized anxiety disorders (GAD) have become a focus of clinical research. There is some empirical evidence that cognitive behavior therapy (CBT) is an effective treatment. But the available studies have some shortcomings which do not allow generalizations to treatment under routine conditions. Method: In a multicenter controlled clinical trial supported by the Deutsche Forschungsgemeinschaft, efficacy of manual-guided CBT was studied in cooperation with behavior therapists who work in private practice. The design and methodology of the study adhere to the same rules as are valid in pharmacotherapy trials. Patients treated with CBT (TA) were compared with those of a waiting contact group (KKG). Because the control group patients were also treated with CBT after the waiting period (TB), a validation of treatment results has been possible. 72 outpatients (age 18–65 years, HAM-A ≧ 18, GAD according to DSM-IV, no co-morbid axis-I or axis-II disorders, no co-medication) were included and randomized into the study arms. Results: In TA HAM-A showed a reduction pre-post of 10.64 (39.6%) and STAI state of 7.96 (15.1%). In TB (those patients with delayed start of therapy) the reduction in the HAM-A was 12.08 (56.9%) and in the STAI state 6.62 (13.5%). In KKG the reduction was 1.22 (5.3%) in the HAM-A and 1.63 (3.2%) in the STAI state. Differences between TA or TB and KKG were statistically highly significant. Conclusion: The data show that manual-guided CBT is effective in GAD. Results are statistically significant and clinically meaningful. The study also shows that multicenter trials are also feasible in psychotherapy research.

show abstract

Venlafaxine XR in the treatment of anxiety

Cited by 16 publications

References 9 publications

Don't Ask, Don't Tell, but Benzodiazepines Are Still the Leading Treatments for Anxiety Disorder

Don't Ask, Don't Tell, but Benzodiazepines Are Still the Leading Treatments for Anxiety Disorder

WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder

Wirksamkeit der kognitiven Verhaltenstherapie bei generalisierten Angsterkrankungen – Ergebnisseder Berliner KVT-GAD-Studie

Contact Info

Product

Resources

About